Form 4: Avidity Biosciences CFO MacLean Sells Shares to Cover Tax Obligations

Michael F. MacLean, CFO of Avidity Biosciences, sold 7,935 shares of common stock on March 20, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 20, 2025, Michael F. MacLean, the Chief Financial Officer of Avidity Biosciences, sold 7,935 shares of the company's common stock.
• The sale was executed at a weighted-average price of $31.0554 per share, with individual transactions ranging from $30.78 to $31.06.
• This transaction was to cover tax withholding obligations associated with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on March 19, 2025.
• The RSUs were initially granted as performance-based restricted stock units (PSUs) and converted to time-based RSUs after the company achieved a performance objective on September 19, 2024.
• The sale was mandated by Avidity Biosciences' policy to cover tax obligations through a 'sell-to-cover' transaction, and MacLean has an instruction letter for automatic sales under Rule 10b5-1.
• Following the transaction, MacLean still beneficially owns 96,720 shares of Avidity Biosciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports a routine transaction (sell-to-cover for tax obligations). The vesting of RSUs is a positive sign, but the sale itself is neutral.

Positives

• The 'sell-to-cover' transaction is part of a pre-arranged plan (Rule 10b5-1), suggesting no discretionary trading based on insider information.
• The vesting of RSUs indicates that Avidity Biosciences achieved a performance objective, which is a positive sign for the company's progress.

Negatives

• The sale of shares by a high-ranking officer, even for tax purposes, could be perceived negatively by some investors, although it is a mandated transaction.

Risks

• While the sale is for tax obligations, any significant insider selling could create short-term downward pressure on the stock price.
• The market's reaction to insider sales can be unpredictable, regardless of the reason for the sale.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs suggests continued progress towards company objectives.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Insider transactions are common in publicly traded companies, especially related to equity compensation. The 'sell-to-cover' mechanism is a standard practice to manage tax obligations for employees receiving stock-based compensation.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies, including biotechnology firms like Amgen, Gilead Sciences, and Biogen, to manage tax obligations for employees receiving stock-based compensation.
• The use of Rule 10b5-1 plans is also a standard practice to avoid accusations of insider trading, as seen in companies like Vertex Pharmaceuticals and Regeneron Pharmaceuticals.

Stakeholder Impact

• The sale could have a minor short-term impact on shareholders due to potential downward pressure on the stock price.
• Employees who hold RSUs may be interested in the company's 'sell-to-cover' policy for managing tax obligations.

Key Dates

Keywords

Avidity Biosciences, RNA, Michael F. MacLean, CFO, Form 4, Insider Trading, Sell-to-Cover, Restricted Stock Units, RSUs, PSUs, Rule 10b5-1, Tax Withholding